CBP-1018 is under clinical development by Coherent Biopharma and currently in Phase I for Bone Metastasis. According to GlobalData, Phase I drugs for Bone Metastasis have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CBP-1018’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CBP-1018 overview
CBP-1018 is under development for the treatment of metastatic castration resistant prostate cancer, advanced renal cell cancer, advanced lung squamous cell cancer, bladder cancer, ureter cancer, bone metastasis and other advanced solid tumors. It is administered through intravenous drip route. The drug candidate is a FR Alpha/TRPV6 peptide-drug conjugate to monomethyl auristatin E (MMAE).
Coherent Biopharma overview
Coherent Biopharma is a clinical-stage biopharmaceutical company engaged in development and commercialization of bi-targeting XDC drugs which are targets tumor ligand-mediated drugs and tumor markers. The company is headquartered in Suzhou, Jiangsu, China.
For a complete picture of CBP-1018’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
